Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Antimicrobial Resistance Diagnostics Market, by Technology
1.4.2 Europe Antimicrobial Resistance Diagnostics Market, by End User
1.4.3 Europe Antimicrobial Resistance Diagnostics Market, by Pathogen
1.4.4 Europe Antimicrobial Resistance Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. Europe Antimicrobial Resistance Diagnostics Market by Technology
4.1 Europe PCR Market by Country
4.2 Europe Immunoassay Market by Country
4.3 Europe NGS Market by Country
4.4 Europe Microbiology Culture Market by Country
4.5 Europe Mass Spectrometry Market by Country
4.6 Europe Rapid & Point of Care Market by Country
4.7 Europe Others Market by Country
Chapter 5. Europe Antimicrobial Resistance Diagnostics Market by End-user
5.1 Europe Hospitals Market by Country
5.2 Europe Diagnostic Laboratories Market by Country
5.3 Europe Pharmaceutical, Biotechnology Companies & Others Market by Country
Chapter 6. Europe Antimicrobial Resistance Diagnostics Market by Pathogen
6.1 Europe Methicillin Resistant Staphylococcus Aureus (MRSA) Market by Country
6.2 Europe Clostridium Difficile (CD) Market by Country
6.3 Europe Drug Resistant Campylobacter (DRC) Market by Country
6.4 Europe Drug Resistant Streptococcus Pneumoniae (DRSP) Market by Country
6.5 Europe Drug Resistant Neisseria Gonorrhoeae (DRNG) Market by Country
6.6 Europe Drug Resistant Salmonella (DRNTS) Market by Country
6.7 Europe Others Market by Country
Chapter 7. Europe Antimicrobial Resistance Diagnostics Market by Country
7.1 Germany Antimicrobial Resistance Diagnostics Market
7.1.1 Germany Antimicrobial Resistance Diagnostics Market by Technology
7.1.2 Germany Antimicrobial Resistance Diagnostics Market by End-user
7.1.3 Germany Antimicrobial Resistance Diagnostics Market by Pathogen
7.2 UK Antimicrobial Resistance Diagnostics Market
7.2.1 UK Antimicrobial Resistance Diagnostics Market by Technology
7.2.2 UK Antimicrobial Resistance Diagnostics Market by End-user
7.2.3 UK Antimicrobial Resistance Diagnostics Market by Pathogen
7.3 France Antimicrobial Resistance Diagnostics Market
7.3.1 France Antimicrobial Resistance Diagnostics Market by Technology
7.3.2 France Antimicrobial Resistance Diagnostics Market by End-user
7.3.3 France Antimicrobial Resistance Diagnostics Market by Pathogen
7.4 Russia Antimicrobial Resistance Diagnostics Market
7.4.1 Russia Antimicrobial Resistance Diagnostics Market by Technology
7.4.2 Russia Antimicrobial Resistance Diagnostics Market by End-user
7.4.3 Russia Antimicrobial Resistance Diagnostics Market by Pathogen
7.5 Spain Antimicrobial Resistance Diagnostics Market
7.5.1 Spain Antimicrobial Resistance Diagnostics Market by Technology
7.5.2 Spain Antimicrobial Resistance Diagnostics Market by End-user
7.5.3 Spain Antimicrobial Resistance Diagnostics Market by Pathogen
7.6 Italy Antimicrobial Resistance Diagnostics Market
7.6.1 Italy Antimicrobial Resistance Diagnostics Market by Technology
7.6.2 Italy Antimicrobial Resistance Diagnostics Market by End-user
7.6.3 Italy Antimicrobial Resistance Diagnostics Market by Pathogen
7.7 Rest of Europe Antimicrobial Resistance Diagnostics Market
7.7.1 Rest of Europe Antimicrobial Resistance Diagnostics Market by Technology
7.7.2 Rest of Europe Antimicrobial Resistance Diagnostics Market by End-user
7.7.3 Rest of Europe Antimicrobial Resistance Diagnostics Market by Pathogen
Chapter 8. Company Profiles
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Becton, Dickinson and Company
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.3 BioMérieux S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition, Joint Ventures and Mergers:
8.4 F. Hoffmann-La Roche Ltd.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Acquisition and Mergers:
8.5 Danaher Corporation
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Hologic, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Financial Analysis
8.6.4 Segmental and Regional Analysis
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.6.5.2 Acquisition and Mergers:
8.7 Vela Diagnostics Pte. Ltd. (Luye Medical Group Co., Ltd)
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Product Launches and Product Expansions:
8.8 Molsid SAS
8.8.1 Company Overview
8.9 Visby Medical, Inc.
8.9.1 Company Overview
8.10. Accelerated Technology Laboratories, Inc.
8.10.1 Company Overview
Unique Offerings 
